WELCOME > Product > Oncology - Liquid biopsy

Oncology - Liquid biopsy

PANAMutyper™ R EGFR

Lung cancer is a metastatic cancer which the cancer cells are developed in the bronchial tubes or alveoli and grow along the blood vessel or lymphatic vessel. There are two types of lung cancer based on the sizes and shape of the cancer cell; non-small cell lung cancer (NSCLC) takes 75% and small cell lung cancer takes 25%. Usually, it is hard to find lung cancer in the early stage and is diagnosed as lung cancer when it is already progressed. So the prognosis tends to be bad. It is known that the patients with EGFR mutation show very high drug responses against EGFR tyrosine kinase inhibitor (TKI) such as Gefitinib (Iressa, AstraZenca) and Erlotinib (Tarceba, Roche). We expect that genotyping EGFR genes of the lung cancer patients enables predicting drug response before treatment and this will lead effective lung cancer treatment.
CAT NO.
PNAR-3001

DETAILS

 

  
  

Total 47 EGFR Mutations can be detected and discriminated. 

 

 Mutations

 Size

 Exon 18

 Exon 19

 Exon 20

 Exon 21

 24 tests

 G719X

E19del 

T790M 

S768I 

E20ins 

L858R 

L861Q 

 3

29 

10 

 

 

FEATURES

  • 01Multiplex genotyping with a sample
  • 02High sensitivity and specificity even with small amount of ctDNA (0.1% LOD with 2 ml plasma)
  • 03Short running time (within 3 hours)

PROCEDURE

  • sample preparation
  • Extraction of Total DNA
  • real time PCR
  • Analysis of Result

COMPATIBLE SAMPE TYPE

- FFPE tissue
- Plasma

COMPATIBLE Real-Time PCR machine

  • CFX96
(Bio-Rad)
의 이미지

    CFX96
    (Bio-Rad)

  • QuantStudio5
(Thermo Fisher Scientific)의 이미지

    QuantStudio5
    (Thermo Fisher Scientific)

‘*’ marked information should be submitted.